Secondary Pharmaceutical Patenting: A Global Perspective

Bhaven N. Sampat, Kenneth C. Shadlen

NBER Working Paper No. 23114
Issued in January 2017
NBER Program(s):Productivity, Innovation, and Entrepreneurship

Pharmaceutical firms’ use of secondary patents to extend periods of exclusivity generates concerns among policymakers worldwide. In response, some developing countries have introduced measures to curb the grant of these patents. While these measures have received considerable attention, there is limited evidence on their effectiveness. We follow a large sample of international patent applications in the US, Japan, the European Patent Office, and corresponding filings in three developing countries with restrictions on secondary patents, India, Brazil, and Argentina. We examine cross-country comparisons of primary vs. secondary grant rates, consider the differential fates of “twin” applications filed in multiple countries, and undertake detailed analyses of patent prosecution in the three developing countries. Our analyses indicate that measures to restrict secondary patents in developing countries are having limited impact. In none of these three countries are specific policies toward secondary patents the principal determinant of grant rates. Our analyses also suggest the importance of other procedural aspects of patent systems, beyond the formal policies targeting secondary applications, that affect outcomes for these applications in developing countries.

You may purchase this paper on-line in .pdf format from ($5) for electronic delivery.

Access to NBER Papers

You are eligible for a free download if you are a subscriber, a corporate associate of the NBER, a journalist, an employee of the U.S. federal government with a ".GOV" domain name, or a resident of nearly any developing country or transition economy.

If you usually get free papers at work/university but do not at home, you can either connect to your work VPN or proxy (if any) or elect to have a link to the paper emailed to your work email address below. The email address must be connected to a subscribing college, university, or other subscribing institution. Gmail and other free email addresses will not have access.


Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w23114

Published: Bhaven N. Sampat & Kenneth C. Shadlen, 2017. "Secondary pharmaceutical patenting: A global perspective," Research Policy, vol 46(3), pages 693-707.

Users who downloaded this paper also downloaded* these:
Williams w23088 How Do Patents Affect Research Investments?
de Rassenfosse and Jaffe w23072 Econometric Evidence on the R&D Depreciation Rate
Hermalin and Weisbach w23121 Assessing Managerial Ability: Implications for Corporate Governance
Black, Breining, Figlio, Guryan, Karbownik, Nielsen, Roth, and Simonsen w23062 Sibling Spillovers
Farre-Mensa, Hegde, and Ljungqvist w23268 What is a Patent Worth? Evidence from the U.S. Patent “Lottery”
NBER Videos

National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email:

Contact Us